M1835 Nighttime GERD: Prevalence, Symptom Intensity and Treatment Response to a 4 Week Treatment with 40 Mg of Pantoprazole Magnesium O.D. a Report from the GERD Mexican Working Group

Morales-Arámbula, M.; Sobrino-Cossío, Sergio; Vargas, Jose-Antonio; López-Alvarenga, Juan Carlos; Soto-Perez, Julio-Cesar; López‐Colombo, Aurelio; Teramoto-Matsubara, Óscar; Crespo, Yasmin; Ramirez, Armando; Gonzalez, Jorge; Orozco-Gamiz, Antonio; Comuzzie, Anthony G.; López-Salazar, Luis H; Ector, Ramirez-Barba

doi:10.1016/s0016-5085(09)61970-3

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptom intensity improvements in patients experiencing night-time symptoms are shown in Figure 4 18. The effect size of patients' symptom response in the group with night-time symptoms versus those with daytime symptoms, as assessed by the physicians, showed the following.…”

Section: Resultsmentioning

confidence: 90%

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

López-Alvarenga

Orr

Vargas-Romero³

et al. 2014

J Neurogastroenterol Motil

Self Cite

View full text Add to dashboard Cite

Background/AimsTo evaluate the effectiveness of pantoprazole magnesium (pantoprazole-Mg) 40 mg in the relief of esophageal and extra-esophageal symptoms of gastroesophageal reflux disease (GERD), particularly night-time symptoms.MethodsPatients (aged 18-50 years) with 3-month history of heartburn and/or acid regurgitation plus at least one other symptom in the last week were enrolled in a nationwide, prospective and observational study in Mexico. Patients received pantoprazole-Mg 40 mg once daily during 4 weeks. Symptoms were assessed through a physician-administered structured interview and the patient-completed ReQuest in Practice™ questionnaire. Night-time GERD was defined as arousal from sleep during the night due to GERD-associated symptoms.ResultsOut of 4,343 patients included at basal visit, 3,665 were considered for the effectiveness per protocol analysis. At baseline, patients had a median of 8 GERD related symptoms. Patients with night-time GERD symptoms (42.7%) were more likely to have extra-esophageal symptoms (P < 0.001) than other GERD patients. Pantoprazole-Mg 40 mg once daily for 4 weeks improved a broad range of GERD-associated symptoms from baseline (80% reduction on physicians assessments; 68-77% reduction on ReQuest in Practice™ dimensions), including both day- and night-time GERD symptoms; improvements were the greatest for extra-esophageal symptoms in patients with night-time symptoms. Pantoprazole-Mg was well tolerated.ConclusionsPantoprazole-Mg 40 mg significantly improved a broad range of esophageal and extra-esophageal GERD related symptoms including sleep disturbances, as well as well-being, in patients with daytime or night-time GERD, making it a good option for patients with GERD, especially when extra-esophageal and night-time symptoms are present.

show abstract

Section: Resultsmentioning

confidence: 90%

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

López-Alvarenga

Orr

Vargas-Romero³

et al. 2014

J Neurogastroenterol Motil

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pantoprazole-Mg, in particular, continued to improve sleep from week 4 to week 8. Similar improvements in sleep disturbances, along with patient well-being, were observed in association with significant improvements in a broad range of oesophageal and extra-oesophageal GERDrelated symptoms in a previous, large, observational study in which patients with day-time or night-time GERD received pantoprazole-Mg. 27,28 Together, these data suggest that pantoprazole-Mg may be an important treatment option for maintaining patient satisfaction and improving HRQoL, which worsen with more severe disease as well as in the presence of atypical GERD symptoms and/or night-time GERD. 29 Both pantoprazole-Mg and esomeprazole were well tolerated, with no unexpected safety concerns.…”

Section: Discussionmentioning

confidence: 96%

Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms

Moraes-Filho

Pedroso²,

Quigley

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In the Mexican study the symptoms were evaluated through ReQuest (specific questionnaire that assesses GERD symptoms) results obtained showed that symptoms intensity improved with pantoprazole 40 mg o.d treatment during 4 weeks, regardless of the predominance of daytime symptoms or night (54). Table III shows the data from an interim analysis (with 3,306 GERD patients) that was performed as part of this study.…”

Section: Clinical Evidencementioning

confidence: 99%

“…A Cochrane Review (48) of 134 controlled clinical trials (CCT) (n = 36,978) reported that PPIs are more effective than H2RAs and placebo in healing esophagitis, controlling symptoms and decreasing the rate of recurrence, with no significant differences among them and a modest gain when doubling the dose (54,55). Table IV shows the percentages of intragastric pH control in different clinical trials (56,57).…”

Section: Clinical Evidencementioning

confidence: 99%

See 1 more Smart Citation

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Sobrino-Cossío

López-Alvarenga

Remes-Troche

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

The Montreal Definition and Classification divides Gastroesophageal Reflux Disease (GERD) into esophageal symptomatic syndromes (and with mucosal damage) and extraesophageal syndromes (with acid established association and proposed association). In typical GERD symptoms, an 8-week treatment with PPIs is satisfactory in most cases (> 90%). Response rates to PPIs in GERD are highly variable, as they also rely on an appropriate clinical diagnosis of the disease; endoscopy differentiates the macroscopic GERD phenotype. The non-erosive variety (50-70% prevalence) has a different symptomatic response rate, as gastric acid is not the sole etiology of symptoms. The possible explanations of treatment failure include treatment adherence, PPI metabolism alterations and characteristics, and inadequate diagnosis. Refractory symptoms are related to gastric content neutralization by the chronic use of PPIs.Extraesophageal manifestations are associated with other pathophysiological mechanisms where an autonomic nervous system disturbance gives rise to symptoms. In these clinical entities, the relationship between symptoms and acid needs to be established in order to determine the use of PPIs, or consider other drugs. In other words, so as to "custom-tailor the best-fitting therapy" we need to answer the questions for whom, for what, how and for how long. Finally, PPI safety and tolerability are factors to be considered in elderly patients requiring chronic PPI use, who usually have chronic concomitant illnesses.

show abstract

M1835 Nighttime GERD: Prevalence, Symptom Intensity and Treatment Response to a 4 Week Treatment with 40 Mg of Pantoprazole Magnesium O.D. a Report from the GERD Mexican Working Group

Cited by 5 publications

References 0 publications

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms

Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen

Contact Info

Product

Resources

About